Clinical trial

Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection

NCT06276504

Study summary

ClinicalTrials.gov

Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2, PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection Find medicine records · Find other trials using this name

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2024-04-01

PhasePHASE2 / PHASE3

Conditions

Progressive Multifocal Leukoencephalopathyverified · MONDO: progressive multifocal leukoencephalopathy

Interventions

Pembrolizumab, 25 mg/ml solution for intravenous (IV) injectionDRUG

Sponsors & collaborators

Assistance Publique - Hôpitaux de Parislead sponsor

Mapped research locations

ParisFrance3

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06276504 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.